Not unexpectedly, pre-trial rhetoric has amounted to bullying and posturing in the media's eye, ... prominent reputation includes no apparent lack of shyness as far as communicating with the media and outside observers is concerned.
With Pfizer's diversified product portfolio and cash position that can be used for future deals, we would expect the company to be able to absorb the financial impact.
Bristol-Myers' dividend has been an important attraction for value minded investors -- providing the key back-stop for shares even amidst the company's near-term negative growth outlook and lackluster pipeline news.
Now is about the right time where he does have to become more visible as a CEO.
It will take more verdicts to tell whether trying every case individually is sustainable or needs to be revisited in light of plaintiff victories.
The diabetes market appears poised to post accelerating growth over the coming years.
Copyright © 2024 Electric Goat Media. All Rights Reserved.